Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663110 | 0.79 | MEN1 (0.48) | MEN1KMT2AREN | |
| SCHEMBL7595073 | 0.77 | KDM4E (0.43) | MEN1KMT2AKCNH2 | |
| SCHEMBL1071895 | 0.74 | KCNH2 (0.35) | MEN1KMT2ARENKCNH2 | |
| SCHEMBL10574273 | 0.72 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL1071649 | 0.71 | MEN1 (0.31) | MEN1KMT2ARENKCNH2 | |
| SCHEMBL1071428 | 0.71 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL5070887 | 0.66 | ALDH1A1 (0.52) | KMT2A | |
| SCHEMBL1072910 | 0.66 | REN (0.37) | MEN1KMT2ARENKCNH2 | |
| SCHEMBL1518151 | 0.66 | MTNR1A (0.45) | — | |
| SCHEMBL6985196 | 0.66 | IDO1 (0.50) | MEN1KMT2AREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2300453-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009140769-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | MEN1 4539/4885KMT2A 3129/4885REN 1/4885 |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, AGTR1 | MEN1 4624/4885KMT2A 3927/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.